Search

Mergers and Acquisitions Mergers and Acquisitions Boom in the Pharmaceutical Industry

| Editor: Dominik Stephan

Merger and acquisitions in the pharmaceutical industry have increased by 26.1 percent, compared to the rather mixed development of 2012. More than $ 141 billion were spend on company acquisitions last year...

Related Companies

Global M&A activity in the Pharma, Medical & Biotech (PMB) has increased 26.1% compared to the same period in 2012 (up until end of October) with US$ 141bn-worth of deals compared to US$ 111.8bn this time last year.
Global M&A activity in the Pharma, Medical & Biotech (PMB) has increased 26.1% compared to the same period in 2012 (up until end of October) with US$ 141bn-worth of deals compared to US$ 111.8bn this time last year.
(Source: Mergermarket)

After M&A activities fell sharply during 2012, the pharmaceutical branch looks more confidently into the future: Although investments gave in slightly towards the end of 2012, they were still significantly above 2012's values, recent Mergermarket figures show. The highest valued deal so far was the $ 15 billion acquisition of Life Technologies by Thermo Fisher - a transaction tat should significantly increase Thermo's market shares in Asia.

The majority of mergers and acquisitions were witnessed once again in the US (57.7 percent or US $ 81 billion), yet this share was the lowest since 2012. Asian companies meanwhile are increasingly growing by acquisition, though still mostly in their domestic markets. With US $ 4.2 billion, M&A activities in China are a major driving force behind the US $ 12.6 billion merger bill of all Asia. Europe's pharma and biotech market expanded to US 43.8 billion in 2012, in part through incoming deals.

Gallery
Gallery with 5 images

(ID:42403328)